|Day Low/High||12.15 / 12.48|
|52 Wk Low/High||6.25 / 13.76|
Recro Pharma Inc., which makes drugs such as Ritalin LA for Novartis, looks healthy going into 2020.
So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
It's a process that involves harvesting gains by repeatedly writing call options against stocks steadily in decline.
The Chinese government has now demonstrated an ability to control the S&P 500, even at the risk of Chinese domestic capital flight.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
Be careful backing Buffett right now, his biggest holdings show increasing profit pressure.
When traders are flailing and investors are drowning, examples work best to illustrate what happens before a bottom is reached.
If you get down on yourself in some of your trades and investments - check out the 2-3 year chart on Teva Pharmaceuticals . And consider that The Oracle of Omaha, Warren Buffett, owns over 43 million shares. I have been negative on fundamental groun...
Do not try to pick a bottom on this stock.
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
Before I jump on the radio, here's a quick list of upgrades, downgrades and new research coverage coming out of Wall Street this morning... - Hilltop Holdings upgraded to Overweight from Neutral at Piper Jaffray - Trex upgraded to Buy from Hold at S...
In this day and age, companies must be 'disruptors' or get left in the dust.
There is still no news on China trade, so keep your chinstrap buckled and wear your flak jacket.
China trade discussions will continue to be a key driver in Wednesday's market action.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
Jim Cramer was bearish on TEVA.
Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.
Eli Lilly's excellent earnings weren't excellent enough.
The giant drugmaker raised its profit guidance for all of 2018 after its third-quarter results beat expectations.
Santa is on his way... A lot of pressure on the jolly fellow this year.